Showing results (141-150 of 318) with videos related to
Sort By:
Pageof 32
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 9, 2021
Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic featuresNatalie M Rizzo, Lynette M Sholl, Muhammad T Idrees, et al.Cancer Cytopathology|October 9, 2023
Validation of targeted next-generation sequencing of cell-free DNA from archival cerebrospinal fluid specimens for the detection of somatic variants in cancer involving the leptomeninges: Cytopathologic and radiographic correlationAlexander J Neil, Ugonma N Chukwueke, Nicholas Hoover, et al.The American Journal of Surgical Pathology|June 12, 2026
Clinicopathologic Study of 39 Mismatch Repair-deficient Sarcomas Demonstrates Recurrent Histologic Patterns and Supports Universal Screening of Pleomorphic Rhabdomyosarcoma, Uterine Leiomyosarcoma, and Undifferentiated and Unclassified SarcomasIgor Odintsov, Jonathan A Nowak, Esther Baranov, et al.Nature Reviews. Clinical Oncology|February 13, 2021
PD-L1 as a biomarker of response to immune-checkpoint inhibitorsDeborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 16, 2022
Molecular assessment of paratesticular rhabdomyomas demonstrates recurrent findings, including a novel H3C2 p.K37I mutationAndres M Acosta, Jesse K McKenney, Lynette M Sholl, et al.CA: a Cancer Journal for Clinicians|March 1, 2023
Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guideAdam H Fox, Mizuki Nishino, Raymond U Osarogiagbon, et al.Lung Cancer (Amsterdam, Netherlands)|December 20, 2019
Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomasJacob M Sands, Tom Nguyen, Priyanka Shivdasani, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation ConsortiumRobin Guo, Lynne D Berry, Dara L Aisner, et al.Cell|August 2, 2014
The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancyRuth Scherz-Shouval, Sandro Santagata, Marc L Mendillo, et al.Personalized Medicine|August 1, 2017
The fuzzy world of precision medicine: deliberations of a precision medicine tumor boardSarah A McGraw, Judy Garber, Pasi A Jänne, et al.Pageof 32